PAPERS AllCitationsDrug OverdoseHealth InsuranceHealthcare Innovation and ValueInfectious DiseaseIssue BriefsMortality and LongevityPapersPharmaceutical MarketPolicy BriefsRegulation COVID-19 Biopharmaceutical Innovation and Industry AppropriationHealthcare Innovation and Value, Infectious Disease, Pharmaceutical Market, Regulation New Bipartisan Legislation, “Ensuring Pathways to Innovative Cures (EPIC) Act,” Introduced to Eliminate IRA “Pill Penalty” and Support Small Molecule Drug Innovation, Cites Philipson Policy BriefCitations Difference-in-Differences in the Marketplace | February 2024Drug Overdose, Healthcare Labor Supply, Mortality and Longevity The Value of Accelerated Medical Device Reimbursement | November 2023Healthcare Innovation and Value, Issue Briefs, Papers, Regulation Policy Brief: The Impact of Price Setting at 9 Years on Small Molecule Innovation Under the Inflation Reduction Act | October 2023Healthcare Innovation and Value, Policy Briefs, Regulation Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending | September 2023Health Insurance, Papers, Pharmaceutical Market Policy Brief: The Potentially Larger Than Predicted Impact of the IRA on Small Molecule R&D and Patient Health | August 2023Policy Briefs, Regulation The Value of Medical Innovation in the Fight Against COVID-19 in the United States | August 2023Healthcare Innovation and Value, Infectious Disease, Papers Mulligan, Philipson Cited in the 2023 Joint Economic Report | Report of the Joint Economic Committee Congress of the United States on the 2023 Economic Report of the President | 7/27/2023Citations Mulligan, Philipson Cited in the 2023 Joint Economic Report | Report of the Joint Economic Committee Congress of the United States on the 2023 Economic Report of the President Republican Response | 6/27/2023Citations Evaluating the Economic Impact of CMS coverage Delays for New Alzheimer’s Drugs | June 2023Papers, Pharmaceutical Market, Regulation Beyond Pigou: externalities and civil society in the supply–demand framework | May 2023Infectious Disease, Journal Publication, Papers, Pharmaceutical Market Policy Brief: The Role of Medical Innovation in Reducing Health Disparities and the Impact of the Inflation Reduction Act | February 2023Healthcare Innovation and Value, Policy Briefs, Regulation Restrict the Middleman? Quantitative Models of PBM Regulations and their Consequences | February 2023Policy Briefs, Regulation The Value of Innovation Delaying the Progression of Alzheimer’s Disease in the US | November 2022Healthcare Innovation and Value, Papers Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation | November 2022Health Insurance, Infectious Disease, Journal Publication, Papers Prices and Federal Policies in Opioid Markets | October 2022Drug Overdose, Journal Publication, Papers, Pharmaceutical Market, Regulation The Impact of Biopharmaceutical Innovation on Health Care Spending | August 2022Healthcare Innovation and Value, Papers, Pharmaceutical Market The Value of Pharmacy Benefit Management | July 2022Health Insurance, Papers, Pharmaceutical Market Policy Brief: The Impact of Recent White House Proposals on Cancer Research | June 2022Healthcare Innovation and Value, Policy Briefs, Regulation Mulligan Cited in the 2022 Joint Economic Report | Report of the Joint Economic Committee Congress of the United States on the 2022 Economic Report of the President | 6/23/2022Citations Non-Covid Excess Deaths, 2020-21: Collateral Damage of Policy Choices? | June 2022Drug Overdose, Infectious Disease, Papers, Regulation A Final Report Card on the States’ Response to COVID-19 | April 2022Articles, Infectious Disease, Regulation Lethal Unemployment Bonuses? Substitution and Income Effects on Substance Abuse, 2020-21 | February 2022Drug Overdose, Infectious Disease, Papers, Regulation The Patient Impact of Manufacturing Copay Assistance in an Era of Rising Out-of-Pocket Costs | December 2021Health Insurance, Papers, Regulation Issue Brief: The Impact of HR 5376 on Biopharmaceutical Innovation and Patient Health | November 2021Healthcare Innovation and Value, Issue Briefs, Pharmaceutical Market, Regulation Issue Brief: The Impact of HR 5376 on Antiviral Innovation and Patient Health | November 2021Healthcare Innovation and Value, Papers, Pharmaceutical Market, Regulation Issue Brief: The Evidence Base on The Impact of Price Controls on Medical Innovation | September 2021Healthcare Innovation and Value, Papers, Regulation Issue Brief: A Review of the Scientific Literature on the Value of Health | August 2021Healthcare Innovation and Value, Issue Briefs The Incidence and Magnitude of the Health Costs of In-person Schooling during the COVID-19 Pandemic | July 2021Infectious Disease, Papers, Regulation Economic Activity and the Value of Medical Innovation during a Pandemic | June 2021Healthcare Innovation and Value, Infectious Disease, Papers The Backward Art of Slowing the Spread? Congregation Efficiencies during COVID-19 | April 2021Healthcare Innovation and Value, Infectious Disease, Papers The Value of Employer-Sponsored Health Insurance | March 2021Health Insurance, Papers, Pharmaceutical Market Deaths of Despair and the Incidence of Excess Mortality in 2020 | December 2020Drug Overdose, Infectious Disease, Mortality and Longevity, Papers Wedges, Labor Market Behavior, and Health Insurance Coverage Under the Affordable Care Act | March 2018Health Insurance, Papers The Employer Penalty, Voluntary Compliance, and the Size Distribution of Firms: Evidence from a Survey of Small Businesses | November 2017Health Insurance, Papers The Upside-down Economics of Regulated and Otherwise Rigid Prices | June 2016Papers, Regulation Adjusting Measures of Economic Output for Health: Is the Business Cycle Countercyclical? | July 2015Healthcare Innovation and Value, Mortality and Longevity, Papers
